Tratamiento de las reacciones cutáneas locales secundarias a ingenol mebutato

[1]  M. Haedersdal,et al.  Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. , 2016, Journal of the American Academy of Dermatology.

[2]  C. Garbe,et al.  Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12‐month study , 2016, British Journal of Dermatology.

[3]  G. Argenziano,et al.  Management of local skin reactions after the application of ingenol mebutate gel for the treatment of actinic keratosis: four illustrative cases , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  B. Berman.  Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis , 2015, Expert opinion on drug safety.

[5]  P. Gerber,et al.  Cosmetic Effects of Ingenol Mebutate Gel in the Treatment of Field-Cancerized Photodamaged Skin. , 2015, Dermatologic Surgery.

[6]  R. Dellavalle,et al.  Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. , 2015, JAMA dermatology.

[7]  A. Ariza,et al.  Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  M. Augustin,et al.  Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. , 2015, Journal of the American Academy of Dermatology.

[9]  M. Lebwohl,et al.  A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis , 2015, International journal of dermatology.

[10]  Ellen S. Marmur,et al.  A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate , 2014, Dermatology and Therapy.

[11]  N. Swanson,et al.  Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. , 2014, Journal of drugs in dermatology : JDD.

[12]  C. Ferrándiz,et al.  Spanish adaptation of the European guidelines for the evaluation and treatment of actinic keratosis. , 2014, Actas dermo-sifiliograficas.

[13]  Aditya K. Gupta,et al.  Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers , 2013, Journal of cutaneous medicine and surgery.

[14]  E. Stockfleth.  The paradigm shift in treating actinic keratosis: a comprehensive strategy. , 2012, Journal of drugs in dermatology : JDD.

[15]  E. Stockfleth,et al.  Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. , 2012, Journal of drugs in dermatology : JDD.

[16]  A. Suhrbier,et al.  Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. , 2012, The Journal of investigative dermatology.

[17]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[18]  S. Tyring,et al.  Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. , 2012, Journal of the American Academy of Dermatology.

[19]  Ryan W. Hick,et al.  From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. , 2012, The Journal of clinical investigation.

[20]  E. Stockfleth,et al.  Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[21]  M. Ulrich,et al.  Emerging drugs for actinic keratosis , 2010, Expert opinion on emerging drugs.

[22]  Andrew Lee,et al.  The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. , 2010, Cancer research.

[23]  J. Lord,et al.  Novel Antileukemic Compound Ingenol 3-Angelate Inhibits T Cell Apoptosis by Activating Protein Kinase Cθ* , 2010, The Journal of Biological Chemistry.

[24]  J. Lord,et al.  Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005) , 2010, Apoptosis.

[25]  R. S. Padilla,et al.  Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. , 2010, Archives of dermatology.

[26]  Ø. Bruserud,et al.  The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity , 2010, Toxins.

[27]  T. Luger,et al.  Predisposing factors of actinic keratosis in a North-West German population. , 2009, European journal of dermatology : EJD.

[28]  E. Tschen,et al.  Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. , 2009, Journal of the American Academy of Dermatology.

[29]  I. Bièche,et al.  Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. , 2009, Cancer research.

[30]  S. Ogbourne,et al.  PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double‐blind, vehicle‐controlled, multicentre, phase IIa study , 2009, The Australasian journal of dermatology.

[31]  E. Raymond,et al.  Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells , 2008, British Journal of Cancer.

[32]  H. Pehamberger,et al.  Development of a treatment algorithm for actinic keratoses: a European Consensus. , 2008, European journal of dermatology : EJD.

[33]  J. Lord,et al.  Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells , 2008, Molecular Cancer Therapeutics.

[34]  D. Kavanagh,et al.  Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate1 , 2006, The Journal of Immunology.

[35]  H. Kerl,et al.  Guidelines for the management of actinic keratoses. , 2006, European journal of dermatology : EJD.

[36]  F. Khanim,et al.  PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. , 2005, Blood.

[37]  P. Hersey,et al.  Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. , 2004, Molecular cancer therapeutics.

[38]  D. Murrell,et al.  A prospective study of the use of cryosurgery for the treatment of actinic keratoses , 2004, International journal of dermatology.

[39]  M. Lebwohl,et al.  Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. , 2004, Journal of the American Academy of Dermatology.

[40]  P. Parsons,et al.  Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. , 2004, Cancer research.

[41]  J. Rosso.  An update on newer topical therapies for actinic keratoses: advances and applications. , 2003 .

[42]  J. Jorizzo,et al.  5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. , 2001, Skin therapy letter.

[43]  M. Johnson,et al.  Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. , 1988, Archives of dermatology.